Retosiban

Retosiban (GSK-221,149-A) is an oral drug which acts as a selective, sub-nanomolar (Ki=0.65 nM) oxytocin receptor antagonist with >1400-fold selectivity over the related vasopressin receptors and is being developed by GlaxoSmithKline for the treatment of preterm labour.